Bharat Biotech homes some of the most brilliant minds in the world and began its work on the
"We believe we have an early mover advantage in developing the Zikavac and we are probably the first in the world to file for global patent for
While quoting a WHO report, Ella said that the dreadful virus is now present in 23 countries and Brazil, which has been hit the hardest, has reported around 3,530 cases of the disease caused due to it.
"We hope to announce the arrival of Zikavac to the world as early as possible," he said.
Zika virus is spread by mosquitoes of the Aedes genus, which can breed in a pool of water as small as a bottle cap. The mosquito usually bites during the day, and the transmitted infection is related to Dengue, Yellow Fever and West Nile virus.
"Considering that women of child-bearing age and pregnant women are the prime target group for Zika virus vaccine, we consider safety as the overriding factor in development of a new vaccine for this virus. The vaccine methods developed early on, before the devastating consequences of the epidemics in Brazil came to light provided us a push to accelerate vaccine development," Dr Sumathy, Director, R&D, Bharat Biotech said.
As of now, the vaccine maker is focusing towards scaling up and characterizing the vaccine product.
Image source